Characterization of human papillomavirus type 11-specific immune responses in a preclinical model

Keyphrases

• Specific Immune Response 100%
• Human Papillomavirus 11 100%
• Human Papillomavirus Types 100%
• DNA Vaccine 50%
• Recurrent Respiratory Papillomatosis 50%
• CD8+ T Cells 33%
• Immunological Response 33%
• HPV11 33%
• E6 Gene 33%
• E6E7 33%
• Novel Therapeutics 16%
• Patient Demographics 16%
• Papillomavirus Infections 16%
• Plasmid 16%
• C57BL 16%
• Epitope 16%
• Interferon-α (IFN-α) 16%
• Novel Vaccines 16%
• Vaccine Strategy 16%
• Overlapping Peptides 16%
• MHC Class I 16%
• T Cell Epitope 16%
• Vaccine Target 16%
• Plasmid DNA (pDNA) 16%
• Therapeutic Vaccine 16%
• Flow Cytometry 16%
• Splenocytes 16%
• Immunogenic 16%
• Persistent Disease 16%
• Prophylactic Vaccine 16%
• E6 Protein 16%
• Human Papillomavirus 6 16%
• E7 Gene 16%
• DNA Vaccination 16%
• Antigen-specific T Cell Response 16%
• E7 Protein 16%
• Viral Types 16%
• Therapeutic DNA Vaccine 16%
• E7 Peptide 16%
• Specific T Cells 16%

Immunology and Microbiology

• Immune Response 100%
• Human Papillomavirus Type 11 100%
• DNA Immunization 50%
• Peptides 40%
• Cytotoxic T-Cell 20%
• Plasmid 20%
• Epitope 20%
• T Cell 20%
• Interferon Type I 10%
• Splenocyte 10%
• Wart Virus 10%
• C57BL 6 Mouse 10%
• MHC Class I 10%
• Human Papillomavirus Type 6 10%
• DNA Vaccination 10%
• Vertebral Column 10%